24 results
8-K/A
EX-99.1
NKTX
Nkarta, Inc.
15 Aug 24
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
7:12pm
equivalents, restricted cash, and investments in marketable securities of $426.7 million as of June 30, 2024.
Research and development (R&D) expenses were … $23.1 million for the second quarter of 2024. Non-cash stock-based compensation expense included in R&D expense was $2.2 million for the second
8-K
EX-99.1
NKTX
Nkarta, Inc.
13 Aug 24
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
4:05pm
equivalents, restricted cash, and investments in marketable securities of $426.7 million as of June 30, 2024.
Research and development (R&D) expenses were … $23.1 million for the second quarter of 2024. Non-cash stock-based compensation expense included in R&D expense was $2.2 million for the second
8-K
EX-99.1
NKTX
Nkarta, Inc.
16 Jul 24
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
6:30am
-designated oversight of the R&D organization – in addition to his prior responsibilities leading the clinical development, regulatory and translational
8-K
EX-99.1
NKTX
Nkarta, Inc.
13 Jun 24
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
4:22pm
Exhibit 99.1
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
Senior R&D leader brings … expert George Vratsanos, M.D., FACR, is joining its board of directors.
Dr. Vratsanos currently serves as Chief Medical Officer and Head of R&D for Jnana
8-K
EX-99.1
NKTX
Nkarta, Inc.
9 May 24
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
4:04pm
, and investments in marketable securities of $450.0 million as of March 31, 2024.
Research and development (R&D) expenses were $25.2 million for the first … quarter of 2024. Non-cash stock-based compensation expense included in R&D expense was $2.2 million for the first quarter of 2024.
General
8-K
EX-99.1
fmbusj91 s0wd
21 Mar 24
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:15pm
8-K
EX-99.1
ncalmsky1qrs7rtt8
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
8-K
EX-99.1
l2gq cz742
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
EX-99.1
v725m8w
10 Aug 23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
7:05am
8-K
EX-99.1
6ao6n8756wvrbxk3
11 May 23
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
4:06pm
8-K
EX-99.1
nhtvku4
9 Nov 22
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:03pm
8-K
EX-99.1
r8fs9qe iptnn3
11 Aug 22
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.1
0298u8nwu406x
12 May 22
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
4:09pm
8-K
EX-99.1
9fc2uxrhwtfn f38h
17 Mar 22
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:11pm
8-K
EX-99.1
wclk3aw123vo3pp eyu
10 Nov 21
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
4:14pm
8-K
EX-99.1
avyd9ctjc0uvk
12 Aug 21
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
4:19pm
8-K
EX-99.1
at0as6kfocjcen2efg5
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
EX-99.1
z9jbpqdbkbi
6 May 21
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
4:24pm